DE60210456T3 - Solubisierung von kapseln polysacchariden - Google Patents
Solubisierung von kapseln polysacchariden Download PDFInfo
- Publication number
- DE60210456T3 DE60210456T3 DE60210456T DE60210456T DE60210456T3 DE 60210456 T3 DE60210456 T3 DE 60210456T3 DE 60210456 T DE60210456 T DE 60210456T DE 60210456 T DE60210456 T DE 60210456T DE 60210456 T3 DE60210456 T3 DE 60210456T3
- Authority
- DE
- Germany
- Prior art keywords
- polysaccharide
- ethanol
- carrier protein
- serogroup
- saccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002775 capsule Substances 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims abstract description 28
- 239000002671 adjuvant Substances 0.000 claims abstract description 10
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims abstract description 8
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 84
- 229920001282 polysaccharide Polymers 0.000 claims description 59
- 239000005017 polysaccharide Substances 0.000 claims description 59
- 150000004676 glycans Chemical class 0.000 claims description 57
- 229960005486 vaccine Drugs 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 33
- 229920001542 oligosaccharide Polymers 0.000 claims description 32
- 150000001720 carbohydrates Chemical class 0.000 claims description 28
- 150000002482 oligosaccharides Chemical class 0.000 claims description 28
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical group [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 230000021615 conjugation Effects 0.000 claims description 12
- 102000014914 Carrier Proteins Human genes 0.000 claims description 11
- 108010078791 Carrier Proteins Proteins 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 11
- 239000003599 detergent Substances 0.000 claims description 11
- 230000007062 hydrolysis Effects 0.000 claims description 11
- 238000006460 hydrolysis reaction Methods 0.000 claims description 11
- 238000000108 ultra-filtration Methods 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 241000588650 Neisseria meningitidis Species 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 8
- 125000002091 cationic group Chemical group 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 5
- 230000001268 conjugating effect Effects 0.000 claims description 3
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 241001174901 Neisseria meningitidis alpha275 Species 0.000 claims 2
- 241000921898 Neisseria meningitidis serogroup A Species 0.000 claims 2
- 241001573069 Neisseria meningitidis serogroup Y Species 0.000 claims 2
- 241000588677 Neisseria meningitidis serogroup B Species 0.000 claims 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical class O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims 1
- 238000007306 functionalization reaction Methods 0.000 claims 1
- 238000004513 sizing Methods 0.000 claims 1
- 230000003381 solubilizing effect Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 abstract description 7
- 239000000872 buffer Substances 0.000 abstract description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 abstract 1
- 229940001007 aluminium phosphate Drugs 0.000 abstract 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- -1 CTAB polysaccharide Chemical class 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000008351 acetate buffer Substances 0.000 description 7
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid group Chemical group C(CCCCC(=O)O)(=O)O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 7
- 238000011026 diafiltration Methods 0.000 description 7
- 125000005647 linker group Chemical group 0.000 description 7
- 238000006116 polymerization reaction Methods 0.000 description 7
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 6
- 239000011574 phosphorus Substances 0.000 description 6
- 229910052698 phosphorus Inorganic materials 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 description 4
- 239000001361 adipic acid Substances 0.000 description 4
- 235000011037 adipic acid Nutrition 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000004737 colorimetric analysis Methods 0.000 description 4
- 238000001212 derivatisation Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical group O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 239000003022 immunostimulating agent Substances 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 125000005629 sialic acid group Chemical group 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- 230000007928 solubilization Effects 0.000 description 3
- 229940031439 squalene Drugs 0.000 description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- NWMHDZMRVUOQGL-CZEIJOLGSA-N almurtide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)CO[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O NWMHDZMRVUOQGL-CZEIJOLGSA-N 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 238000005341 cation exchange Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000006167 equilibration buffer Substances 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000013628 high molecular weight specie Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960005225 mifamurtide Drugs 0.000 description 2
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- 229940066429 octoxynol Drugs 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- YHQZWWDVLJPRIF-JLHRHDQISA-N (4R)-4-[[(2S,3R)-2-[acetyl-[(3R,4R,5S,6R)-3-amino-4-[(1R)-1-carboxyethoxy]-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound C(C)(=O)N([C@@H]([C@H](O)C)C(=O)N[C@H](CCC(=O)O)C(N)=O)C1[C@H](N)[C@@H](O[C@@H](C(=O)O)C)[C@H](O)[C@H](O1)CO YHQZWWDVLJPRIF-JLHRHDQISA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 108010060123 Conjugate Vaccines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000034762 Meningococcal Infections Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- WPNJAUFVNXKLIM-UHFFFAOYSA-N Moxonidine Chemical compound COC1=NC(C)=NC(Cl)=C1NC1=NCCN1 WPNJAUFVNXKLIM-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 108700015872 N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine Proteins 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710199886 Protein 0.5 Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000011138 biotechnological process Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000004520 cell wall skeleton Anatomy 0.000 description 1
- 229960000800 cetrimonium bromide Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000000658 coextraction Methods 0.000 description 1
- 229940031670 conjugate vaccine Drugs 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- BUACSMWVFUNQET-UHFFFAOYSA-H dialuminum;trisulfate;hydrate Chemical compound O.[Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O BUACSMWVFUNQET-UHFFFAOYSA-H 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000037941 meningococcal disease Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
- RYRIMPODRHVEIW-UHFFFAOYSA-N n-(2-phenylethyl)nitramide Chemical compound [O-][N+](=O)NCCC1=CC=CC=C1 RYRIMPODRHVEIW-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- MPNNOLHYOHFJKL-UHFFFAOYSA-N peroxyphosphoric acid Chemical class OOP(O)(O)=O MPNNOLHYOHFJKL-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000011172 small scale experimental method Methods 0.000 description 1
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940031351 tetravalent vaccine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/04—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from fish or other sea animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
- A23J1/205—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey from whey, e.g. lactalbumine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09F—NATURAL RESINS; FRENCH POLISH; DRYING-OILS; OIL DRYING AGENTS, i.e. SICCATIVES; TURPENTINE
- C09F1/00—Obtaining purification, or chemical modification of natural resins, e.g. oleo-resins
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09G—POLISHING COMPOSITIONS; SKI WAXES
- C09G1/00—Polishing compositions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Formation And Processing Of Food Products (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0115176 | 2001-06-20 | ||
| GBGB0115176.0A GB0115176D0 (en) | 2001-06-20 | 2001-06-20 | Capular polysaccharide solubilisation and combination vaccines |
| PCT/IB2002/003191 WO2003007985A2 (en) | 2001-06-20 | 2002-06-20 | Capsular polysaccharide solubilisation and combination vaccines |
| EP02755452.6A EP1401489B2 (en) | 2001-06-20 | 2002-06-20 | Capsular polysaccharide solubilisation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE60210456D1 DE60210456D1 (de) | 2006-05-18 |
| DE60210456T2 DE60210456T2 (de) | 2006-11-16 |
| DE60210456T3 true DE60210456T3 (de) | 2013-09-05 |
Family
ID=9917070
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60237123T Expired - Lifetime DE60237123D1 (de) | 2001-06-20 | 2002-06-20 | Neisseria meningitidis Kombinationimpfstoffe |
| DE60210456T Expired - Lifetime DE60210456T3 (de) | 2001-06-20 | 2002-06-20 | Solubisierung von kapseln polysacchariden |
| DE122010000040C Pending DE122010000040I1 (de) | 2001-06-20 | 2002-06-20 | Solubilisierung von capsulären Polysacchariden |
| DE122011000003C Pending DE122011000003I1 (de) | 2001-06-20 | 2002-06-20 | Neisseria meningitidis Kombinationimpfstoffe |
| DE122010000041C Pending DE122010000041I1 (de) | 2001-06-20 | 2002-06-20 | Solubilisierung von capsulären Polysacchariden |
| DE122010000042C Pending DE122010000042I1 (de) | 2001-06-20 | 2002-06-20 | Solubilisierung von capsulären Polysacchariden |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60237123T Expired - Lifetime DE60237123D1 (de) | 2001-06-20 | 2002-06-20 | Neisseria meningitidis Kombinationimpfstoffe |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE122010000040C Pending DE122010000040I1 (de) | 2001-06-20 | 2002-06-20 | Solubilisierung von capsulären Polysacchariden |
| DE122011000003C Pending DE122011000003I1 (de) | 2001-06-20 | 2002-06-20 | Neisseria meningitidis Kombinationimpfstoffe |
| DE122010000041C Pending DE122010000041I1 (de) | 2001-06-20 | 2002-06-20 | Solubilisierung von capsulären Polysacchariden |
| DE122010000042C Pending DE122010000042I1 (de) | 2001-06-20 | 2002-06-20 | Solubilisierung von capsulären Polysacchariden |
Country Status (23)
| Country | Link |
|---|---|
| US (9) | US8753651B2 (enExample) |
| EP (10) | EP2277539A3 (enExample) |
| JP (4) | JP5075317B2 (enExample) |
| CN (4) | CN100482273C (enExample) |
| AT (3) | ATE322287T1 (enExample) |
| AU (3) | AU2002321716B2 (enExample) |
| BE (4) | BE2010C033I2 (enExample) |
| BR (2) | BR122019009186B8 (enExample) |
| CA (3) | CA2450203C (enExample) |
| CY (6) | CY1110820T1 (enExample) |
| DE (6) | DE60237123D1 (enExample) |
| DK (6) | DK2277536T3 (enExample) |
| ES (9) | ES2387592T5 (enExample) |
| FR (4) | FR10C0043I1 (enExample) |
| GB (1) | GB0115176D0 (enExample) |
| LU (4) | LU91734I2 (enExample) |
| MX (1) | MXPA03011462A (enExample) |
| NL (3) | NL300458I2 (enExample) |
| NZ (2) | NZ544332A (enExample) |
| PT (6) | PT1401489E (enExample) |
| RU (2) | RU2381814C2 (enExample) |
| TR (2) | TR201808055T4 (enExample) |
| WO (1) | WO2003007985A2 (enExample) |
Families Citing this family (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9928196D0 (en) | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
| EP2957300B1 (en) | 2001-01-23 | 2021-07-14 | Sanofi Pasteur Inc. | Multivalent meningococcal polysaccharide-protein conjugate vaccine |
| GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| GB0118249D0 (en) * | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| BR0308768A (pt) * | 2002-03-26 | 2005-02-15 | Chiron Srl | Sacarìdeos modificados possuindo estabilidade melhorada em água |
| MXPA04011249A (es) | 2002-05-14 | 2005-06-06 | Chiron Srl | Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos. |
| GB0302218D0 (en) | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
| WO2004014417A2 (en) * | 2002-08-02 | 2004-02-19 | Glaxosmithkline Biologicals Sa | Vaccine compositions comprising l2 and/or l3 immunotype lipooligosaccharides from lgtb- neisseria minigitidis |
| GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
| SI2353608T1 (sl) | 2002-10-11 | 2020-12-31 | Glaxosmithkline Biologicals Sa | Polipeptidna cepiva za široko zaščito proti hipervirulentnim meningokoknim linijam |
| PT2279746E (pt) | 2002-11-15 | 2013-12-09 | Novartis Vaccines & Diagnostic | Proteínas de superfície de neisseria meningitidis |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| PT2172213E (pt) * | 2003-01-30 | 2013-06-03 | Novartis Ag | Vacinas injetáveis contra múltiplos serogrupos meningocócicos |
| GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
| EP2851088A1 (en) * | 2003-06-23 | 2015-03-25 | Baxter International Inc. | Vaccines against group Y Neisseria meningitidis and meningoccal combinations thereof |
| CA2540896C (en) | 2003-10-02 | 2015-06-02 | Chiron Srl | Liquid vaccines for multiple meningococcal serogroups |
| GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| GB0406013D0 (en) | 2004-03-17 | 2004-04-21 | Chiron Srl | Analysis of saccharide vaccines without interference |
| GB0408978D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Meningococcal fermentation for preparing conjugate vaccines |
| GB0408977D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
| GB0409745D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
| GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
| PL1740217T3 (pl) | 2004-04-30 | 2012-03-30 | Novartis Ag | Szczepienie koniugatem meningokokowym |
| GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
| GB0411387D0 (en) * | 2004-05-21 | 2004-06-23 | Chiron Srl | Analysis of saccharide length |
| GB0413868D0 (en) * | 2004-06-21 | 2004-07-21 | Chiron Srl | Dimensional anlaysis of saccharide conjugates |
| US20060088554A1 (en) * | 2004-08-30 | 2006-04-27 | Ryall Robert P | Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine |
| JP2008513541A (ja) * | 2004-09-21 | 2008-05-01 | サノフィ パストゥール インコーポレイテッド | 多価髄膜炎菌誘導体化多糖−タンパク質複合体およびワクチン |
| GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
| GB0502096D0 (en) * | 2005-02-01 | 2005-03-09 | Chiron Srl | Purification of streptococcal capsular polysaccharide |
| NZ599345A (en) | 2005-02-18 | 2013-07-26 | Novartis Vaccines & Diagnostic | Immunogens from uropathogenic Escherichia Coli |
| SI2351772T1 (sl) | 2005-02-18 | 2016-11-30 | Glaxosmithkline Biologicals Sa | Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso |
| GB0505518D0 (en) * | 2005-03-17 | 2005-04-27 | Chiron Srl | Combination vaccines with whole cell pertussis antigen |
| CN113198012B (zh) | 2005-04-08 | 2024-09-17 | 惠氏有限责任公司 | 多价肺炎球菌多糖－蛋白质缀合物组合物 |
| WO2006113528A2 (en) | 2005-04-18 | 2006-10-26 | Novartis Vaccines And Diagnostics Inc. | Expressing hepatitis b virus surface antigen for vaccine preparation |
| GB0513069D0 (en) * | 2005-06-27 | 2005-08-03 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| EP2201961B1 (en) * | 2005-06-27 | 2018-01-24 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| GB0513071D0 (en) * | 2005-06-27 | 2005-08-03 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| WO2007026249A2 (en) | 2005-09-01 | 2007-03-08 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Multiple vaccination including serogroup c meningococcus |
| EP2208999B1 (en) * | 2005-09-05 | 2014-08-27 | GlaxoSmithKline Biologicals SA | Serum bactericidal assay for N. meningitidis specific antisera |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| KR101411425B1 (ko) | 2006-03-17 | 2014-06-24 | 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 | 복합 다가 면역원성 콘쥬게이트의 제조 방법 |
| GB0605757D0 (en) | 2006-03-22 | 2006-05-03 | Chiron Srl | Separation of conjugated and unconjugated components |
| DK2004225T3 (da) * | 2006-03-22 | 2012-08-06 | Novartis Ag | Programmer for vaccination med meningocockonjugater |
| US10828361B2 (en) * | 2006-03-22 | 2020-11-10 | Glaxosmithkline Biologicals Sa | Regimens for immunisation with meningococcal conjugates |
| TW200806315A (en) * | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
| CN101081296B (zh) * | 2006-05-29 | 2010-08-04 | 北京民海生物科技有限公司 | 一种b型流感嗜血杆菌荚膜多糖制备方法及其联合疫苗 |
| US7491517B2 (en) | 2006-07-19 | 2009-02-17 | Jeeri R Reddy | Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135 |
| RU2322503C1 (ru) * | 2006-07-21 | 2008-04-20 | Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации | Способ получения высокоспецифичной гетерологичной антирабической сыворотки |
| JP2010500399A (ja) | 2006-08-16 | 2010-01-07 | ノバルティス アーゲー | 尿路病原性大腸菌由来の免疫原 |
| KR101467002B1 (ko) * | 2006-10-10 | 2014-12-01 | 와이어쓰 엘엘씨 | 스트렙토코쿠스 뉴모니애 제3형 다당류의 정제 방법 |
| AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
| GB0700136D0 (en) | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Process for manufacturing vaccines |
| GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
| SI2436700T1 (sl) * | 2007-03-23 | 2018-09-28 | Wyeth Llc | Skrajšan postopek čiščenja za proizvodnjo kapsularnih polisaharidov streptococcusa pneumoniae |
| WO2008129559A2 (en) * | 2007-04-23 | 2008-10-30 | Serum Institute Of India Ltd | Antigenic polysaccharides and process for their preparation |
| CA2688268A1 (en) | 2007-06-04 | 2008-12-11 | Novartis Ag | Formulation of meningitis vaccines |
| GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
| CN101896197B (zh) * | 2007-09-11 | 2013-10-23 | 圭尔夫大学 | 来自艰难梭菌的新型多糖免疫原 |
| CA2702871A1 (en) | 2007-10-19 | 2009-04-23 | Novartis Ag | Meningococcal vaccine formulations |
| ES2532946T3 (es) | 2008-02-21 | 2015-04-06 | Novartis Ag | Polipéptidos PUfH meningocócicos |
| CN101724085B (zh) * | 2008-10-22 | 2011-09-21 | 上海生物制品研究所 | 一种荚膜多糖纯化方法 |
| PT2349520T (pt) | 2008-10-27 | 2016-08-16 | Glaxosmithkline Biologicals Sa | Método de purificação para hidrato de carbono de estreptococos grupo a |
| GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
| GB0822633D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
| NZ593674A (en) | 2008-12-17 | 2013-03-28 | Novartis Ag | Meningococcal vaccines including hemoglobin receptor |
| CN104650241A (zh) | 2009-08-27 | 2015-05-27 | 诺华股份有限公司 | 包括脑膜炎球菌fHBP序列的杂交多肽 |
| AU2010352695B2 (en) | 2009-09-30 | 2014-08-21 | Glaxosmithkline Biologicals S.A. | Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides |
| CN102917730A (zh) | 2009-10-27 | 2013-02-06 | 诺华有限公司 | 修饰的脑膜炎球菌fHBP多肽 |
| BR112012010223A2 (pt) * | 2009-10-30 | 2016-12-06 | Novartis Ag | purificação de staphylococcus aureus tipo 5 e tipo 8 sacarídeos capsulares |
| EP2547357A1 (en) | 2010-03-18 | 2013-01-23 | Novartis AG | Adjuvanted vaccines for serogroup b meningococcus |
| PL3246044T5 (pl) | 2010-08-23 | 2024-06-17 | Wyeth Llc | Stabilne preparaty antygenów rLP2086 Neisseria meningitidis |
| WO2012031271A1 (en) | 2010-09-04 | 2012-03-08 | Novartis Ag | Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines |
| PE20140173A1 (es) | 2010-09-10 | 2014-02-20 | Wyeth Llc | Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis |
| GB201101665D0 (en) | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
| US20130315959A1 (en) | 2010-12-24 | 2013-11-28 | Novartis Ag | Compounds |
| TR201811280T4 (tr) | 2011-03-02 | 2018-08-27 | Glaxosmithkline Biologicals Sa | Düşük antijen ve/ veya adjuvan dozları olan karma aşılar. |
| US9149541B2 (en) | 2011-07-08 | 2015-10-06 | Novartis Ag | Tyrosine ligation process |
| CU20110202A7 (es) | 2011-11-02 | 2013-12-27 | Inst Finlay Ct De Investigación Producción De Sueros Y Vacunas | Composición inmunogénica de polisacáridos planos adyuvados y las formulaciones resultantes |
| CN104080479B (zh) * | 2011-11-07 | 2019-11-05 | 葛兰素史密丝克莱恩生物有限公司 | 包括spr0096和spr2021抗原的运载体分子 |
| JP6042455B2 (ja) * | 2012-01-30 | 2016-12-14 | セラム インスティチュート オブ インディア プライベイト リミテッド | 免疫原性組成物の調製方法 |
| CN104159603A (zh) | 2012-03-08 | 2014-11-19 | 诺华股份有限公司 | 带有tlr4激动剂的联合疫苗 |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| EP4043029A1 (en) | 2012-03-09 | 2022-08-17 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| US10124051B2 (en) | 2012-05-22 | 2018-11-13 | Glaxosmithkline Biologicals Sa | Meningococcus serogroup X conjugate |
| WO2014009971A2 (en) * | 2012-07-07 | 2014-01-16 | Bharat Biotech International Limited | Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof |
| CN103623404B (zh) * | 2012-08-28 | 2016-08-03 | 天士力制药集团股份有限公司 | 一种b型流感嗜血杆菌多糖结合疫苗的制备方法 |
| AU2013311702A1 (en) | 2012-09-06 | 2015-02-19 | Novartis Ag | Combination vaccines with serogroup B meningococcus and D/T/P |
| CA2892035C (en) * | 2012-11-21 | 2019-11-05 | Serum Institute Of India Ltd. | Production of neisseria meningitidis x capsular polysaccharide |
| WO2014095771A1 (en) | 2012-12-18 | 2014-06-26 | Novartis Ag | Conjugates for protecting against diphtheria and/or tetanus |
| US9802987B2 (en) | 2013-03-08 | 2017-10-31 | Pfizer Inc. | Immunogenic fusion polypeptides |
| KR20160040556A (ko) | 2013-07-11 | 2016-04-14 | 노파르티스 아게 | 미생물 트랜스글루타미나제를 사용한 리신-특이적 화학효소적 단백질 변형 |
| US9910041B2 (en) | 2013-07-12 | 2018-03-06 | Emd Millipore Corporation | Method of determining virus removal from a sample containing a target protein using activated carbon |
| EP3041502A2 (en) | 2013-09-08 | 2016-07-13 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| EA034954B1 (ru) | 2014-02-28 | 2020-04-10 | Глаксосмитклайн Байолоджикалс Са | МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp |
| EP3148577B1 (en) | 2014-05-24 | 2021-01-20 | Biological E Limited | Novel semi-synthetic meningococcal conjugate vaccine |
| CN104548090B (zh) * | 2015-01-27 | 2016-11-30 | 中国科学院过程工程研究所 | 一种β-葡聚糖修饰的脑膜炎多糖结合疫苗及其制备方法 |
| US10888611B2 (en) | 2015-02-19 | 2021-01-12 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| CN105037579A (zh) * | 2015-08-31 | 2015-11-11 | 成都欧林生物科技股份有限公司 | A群脑膜炎球菌细菌荚膜粗多糖的制备工艺 |
| EP3439704A1 (en) | 2016-04-05 | 2019-02-13 | GSK Vaccines S.r.l. | Immunogenic compositions |
| PH12019500399B1 (en) | 2016-09-02 | 2024-05-15 | Sanofi Pasteur Inc | Neisseria meningitidis vaccine |
| CA3035320A1 (en) | 2016-09-02 | 2018-03-08 | Glaxosmithkline Biologicals Sa | Vaccines for neisseria gonorrhoeae |
| US11951165B2 (en) * | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| US11998599B2 (en) * | 2016-12-30 | 2024-06-04 | Vaxcyte, Inc. | Polypeptide-antigen conjugates with non-natural amino acids |
| JP7010961B2 (ja) | 2017-01-31 | 2022-02-10 | ファイザー・インク | 髄膜炎菌組成物およびその方法 |
| US11246918B2 (en) | 2017-02-03 | 2022-02-15 | Eva Barbara Schadeck | Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof |
| US11400162B2 (en) | 2017-02-24 | 2022-08-02 | Merck Sharp & Dohme Llc | Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein |
| US20200061542A1 (en) * | 2017-02-24 | 2020-02-27 | Merck Sharp & Dohme Corp. | Methods for improving filterability of polysaccharide-protein conjugate reactions |
| UA125937C2 (uk) | 2017-05-05 | 2022-07-13 | Сірем Інстітьют Оф Індіа Прайвет Лімітед | Спосіб видалення домішок з препаратів на основі бактеріальних капсульних полісахаридів |
| WO2018211523A1 (en) * | 2017-05-17 | 2018-11-22 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Purification of bacterial polysaccharides |
| BR112020004410A8 (pt) * | 2017-09-07 | 2023-01-31 | Merck Sharp & Dohme | Processos para a formulação de polissacarídeos pneumocócicos para conjugação a uma proteína carreadora |
| WO2019175900A1 (en) * | 2018-03-16 | 2019-09-19 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Purification of neisseria meningitidis polysaccharides |
| WO2020182635A1 (en) * | 2019-03-08 | 2020-09-17 | Glaxosmithkline Biologicals Sa | Carbocyclic derivatives and conjugated derivatives thereof, and their use in vaccines |
| CN113966234A (zh) | 2019-05-10 | 2022-01-21 | 葛兰素史克生物有限公司 | 缀合物的产生 |
| KR102871663B1 (ko) | 2019-09-27 | 2025-10-16 | 화이자 인코포레이티드 | 네이세리아 메닌기티디스 조성물 및 그의 방법 |
| WO2021099982A1 (en) | 2019-11-22 | 2021-05-27 | Glaxosmithkline Biologicals Sa | Dosage and administration of a bacterial saccharide glycoconjugate vaccine |
| GB202013262D0 (en) | 2020-08-25 | 2020-10-07 | Glaxosmithkline Biologicals Sa | Vaccine Composition |
| CN115721709A (zh) * | 2021-08-27 | 2023-03-03 | 康希诺生物股份公司 | 一种肺炎球菌结合疫苗制备方法 |
| GB202115151D0 (en) | 2021-10-21 | 2021-12-08 | Glaxosmithkline Biologicals Sa | Methods |
| GB202208089D0 (en) * | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| GB202208093D0 (en) | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
Family Cites Families (147)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB207117A (en) | 1923-04-05 | 1923-11-22 | Fernand Prosper Constant Lebru | Improvements in otter boards |
| US4057685A (en) | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
| US4123520A (en) * | 1977-08-01 | 1978-10-31 | Merck & Co., Inc. | Method for preparing high molecular weight meningococcal Group C vaccine |
| US4134214A (en) | 1977-08-05 | 1979-01-16 | Merck & Co., Inc. | Freeze-drying process for the preparation of meningococcus vaccine without degradation of potency |
| DE2748132A1 (de) | 1977-10-27 | 1979-05-03 | Behringwerke Ag | Stabilisator fuer polysaccharid |
| US4220717A (en) * | 1977-12-22 | 1980-09-02 | American Cyanamid Company | Isolation and purification of polyribosyl ribitol phosphate from Haemophilus influenzae type b. |
| US4242501A (en) * | 1979-08-08 | 1980-12-30 | American Cyanamid Company | Purification of pneumococcal capsular polysaccharides |
| US4351762A (en) * | 1981-03-10 | 1982-09-28 | Bioresearch, Inc. | Rapid, quantitative peptide synthesis using mixed anhydrides |
| US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
| BE889979A (fr) | 1981-08-14 | 1982-02-15 | Smith Kline Rit | Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation |
| US4902506A (en) | 1983-07-05 | 1990-02-20 | The University Of Rochester | Immunogenic conjugates |
| US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
| US4451446A (en) * | 1982-03-04 | 1984-05-29 | Smithkline-Rit | Process for the preparation of polysaccharide-protein complexes from bacterial capsules, obtained products and immunogenic compositions containing them |
| US4496538A (en) * | 1982-07-06 | 1985-01-29 | Connaught Laboratories, Inc. | Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine |
| EP0109688A3 (en) | 1982-11-23 | 1986-12-03 | The Wellcome Foundation Limited | Improved complexes, processes for obtaining them and formulations containing such complexes |
| JPS59176214A (ja) * | 1982-11-23 | 1984-10-05 | ザ・ウエルカム・フアウンデ−シヨン・リミテツド | 抗原性組成物 |
| US4459286A (en) | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
| US4663160A (en) | 1983-03-14 | 1987-05-05 | Miles Laboratories, Inc. | Vaccines for gram-negative bacteria |
| US4761283A (en) | 1983-07-05 | 1988-08-02 | The University Of Rochester | Immunogenic conjugates |
| US4762713A (en) * | 1983-07-05 | 1988-08-09 | The University Of Rochester | Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers |
| DE3483957D1 (de) * | 1983-11-21 | 1991-02-21 | Wellcome Found | Komplexe, verfahren zu ihrer herstellung und dieselben enthaltende formulierungen. |
| US4882317A (en) | 1984-05-10 | 1989-11-21 | Merck & Co., Inc. | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency |
| US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
| US4808700A (en) | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
| IT1187753B (it) | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
| US4814276A (en) * | 1986-04-25 | 1989-03-21 | Becton, Dickinson And Company | Selective medium for growth of neisseria |
| US4877613A (en) | 1987-08-05 | 1989-10-31 | Biotech Connections, Inc. | Process for preparing veterinary acellular vaccines against gram-negative nonenteric pathogenic bacilli |
| US4761713A (en) * | 1987-11-06 | 1988-08-02 | North American Philips Corp. | Glycol based mid-volt capacitor |
| GB8815795D0 (en) | 1988-07-02 | 1988-08-10 | Bkl Extrusions Ltd | Glazing bead |
| NL8802046A (nl) | 1988-08-18 | 1990-03-16 | Gen Electric | Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen. |
| DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
| JP3436756B2 (ja) | 1988-12-19 | 2003-08-18 | アメリカン・サイアナミド・カンパニー | 髄膜炎菌のクラスｉの外膜タンパク質のワクチン |
| CA2006700A1 (en) | 1989-01-17 | 1990-07-17 | Antonello Pessi | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
| US4963534A (en) | 1989-05-19 | 1990-10-16 | Merck & Co., Inc. | Process for solubilizing polyanoinic bacterial polysaccharides in aprotic solvents |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| AU651949B2 (en) | 1989-07-14 | 1994-08-11 | American Cyanamid Company | Cytokine and hormone carriers for conjugate vaccines |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| BR9007917A (pt) * | 1989-12-14 | 1992-10-20 | Ca Nat Research Council | Vacina aperfeicoada de conjugado polissacaridico meningogocico |
| SU1750689A1 (ru) * | 1990-05-17 | 1992-07-30 | Научно-исследовательский институт вакцин и сывороток им.И.И.Мечникова | Способ получени полисахаридно-белковой вакцины против NeISSeRIa меNINGIтIDIS серогруппы В |
| DE69113564T2 (de) | 1990-08-13 | 1996-05-30 | American Cyanamid Co | Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff. |
| US5256294A (en) * | 1990-09-17 | 1993-10-26 | Genentech, Inc. | Tangential flow filtration process and apparatus |
| US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
| CA2059692C (en) * | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
| CA2059693C (en) * | 1991-01-28 | 2003-08-19 | Peter J. Kniskern | Polysaccharide antigens from streptococcus pneumoniae |
| DE69231663T2 (de) | 1991-03-12 | 2001-08-23 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Polysaccharid-protein-konjugate |
| HU9400426D0 (en) * | 1991-08-16 | 1994-05-30 | Merck & Co Inc | Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide |
| US5314811A (en) * | 1992-07-13 | 1994-05-24 | Merck & Co., Inc. | Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide |
| FR2682388B1 (fr) | 1991-10-10 | 1995-06-09 | Pasteur Merieux Serums Vacc | Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal. |
| AU3630093A (en) | 1992-03-02 | 1993-10-05 | Biocine S.P.A. | Helicobacter pylori proteins useful for vaccines and diagnostics |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| FI945483A7 (fi) * | 1992-05-23 | 1995-01-20 | Smithkline Beecham Biologicals S A | Hepatiitti B - pinta-antigeenejä ja muita antigeenejä sisältäviä yhdistelmärokotteita |
| CA2138997C (en) | 1992-06-25 | 2003-06-03 | Jean-Paul Prieels | Vaccine composition containing adjuvants |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| AU685443B2 (en) | 1993-03-23 | 1998-01-22 | Smithkline Beecham Biologicals (Sa) | Vaccine compositions containing 3-O deacylated monophosphoryl lipid A |
| ES2210262T3 (es) * | 1993-09-22 | 2004-07-01 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Procedimiento que permite activar un glucido soluble con la ayuda de nuevos reactivos cianilantes para producir estructuras inmunogenas. |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| WO1996001273A1 (en) | 1994-07-01 | 1996-01-18 | Rican Limited | Helicobacter pylori antigenic protein preparation and immunoassays |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| DK0772619T4 (da) | 1994-07-15 | 2011-02-21 | Univ Iowa Res Found | Immunmodulatoriske oligonukleotider |
| GB9422096D0 (en) | 1994-11-02 | 1994-12-21 | Biocine Spa | Combined meningitis vaccine |
| US6696065B1 (en) * | 1995-05-04 | 2004-02-24 | Aventis Pastuer Limited | Acellular pertussis vaccines and methods of preparation thereof |
| BR9608612A (pt) | 1995-06-07 | 1999-05-04 | Smithkline Beecham Biolog | Vacina compreendendo um conjugado de antígeno de polissacarídeo - proteína portadora e proteína portadora livre |
| US20030157129A1 (en) * | 1995-06-23 | 2003-08-21 | Smithkline Beecham Biologicals S.A. | Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein |
| US5811102A (en) * | 1995-06-07 | 1998-09-22 | National Research Council Of Canada | Modified meningococcal polysaccharide conjugate vaccines |
| EP1082965B1 (en) | 1995-06-23 | 2009-06-10 | GlaxoSmithKline Biologicals S.A. | A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate |
| US20020054884A1 (en) * | 1995-06-23 | 2002-05-09 | Smithkline Beecham Biologicals, Sa | Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| ES2283012T3 (es) | 1996-01-04 | 2007-10-16 | Novartis Vaccines And Diagnostics, Inc. | Bacterioferritina de helicobacter pylori. |
| AU2115897A (en) | 1996-02-01 | 1997-08-22 | North American Vaccine, Inc. | Expression of group b neisseria meningitidis outer membrane (mb3) protein from yeast and vaccines |
| CA2245588C (en) * | 1996-02-14 | 2006-05-09 | Russel J. Lander | Polysaccharide precipitation process |
| DE19630390A1 (de) | 1996-07-26 | 1998-01-29 | Chiron Behring Gmbh & Co | Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung |
| PT939647E (pt) * | 1996-08-27 | 2002-04-29 | Chiron Corp | Glicpconjugados do serogrupo b de neisseria meningitidis e metodos de utilizacao dos mesmos |
| US6610661B1 (en) | 1996-10-11 | 2003-08-26 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| US6248334B1 (en) * | 1997-01-08 | 2001-06-19 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process |
| EP0959905B1 (en) * | 1997-01-21 | 2009-12-09 | Sanofi Pasteur | Polysaccharide-peptide-conjugates |
| AU727593B2 (en) * | 1997-01-24 | 2000-12-14 | Schweiz. Serum- & Impfinstitut Bern | Novel method for the isolation of polysaccharides |
| WO1998037919A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
| ATE441432T1 (de) | 1997-03-10 | 2009-09-15 | Ottawa Hospital Res Inst | Verwendung von nicht-methyliertem cpg dinukleotid in kombination mit aluminium als adjuvantien |
| US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
| US6403306B1 (en) | 1997-04-09 | 2002-06-11 | Emory University | Serogroup-specific nucleotide sequences in the molecular typing of bacterial isolates and the preparation of vaccines thereto |
| CA2288267A1 (en) * | 1997-04-24 | 1998-10-29 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Coupling of unmodified proteins to haloacyl or dihaloacyl derivatized polysaccharides for the preparation of protein-polysaccharide vaccines |
| DE69838294T2 (de) | 1997-05-20 | 2009-08-13 | Ottawa Health Research Institute, Ottawa | Verfahren zur Herstellung von Nukleinsäurekonstrukten |
| WO1998054296A1 (en) | 1997-05-28 | 1998-12-03 | Chiron S.P.A. | Culture medium with yeast or soy bean extract as aminoacid source and no protein complexes of animal origin |
| ATE432348T1 (de) | 1997-06-06 | 2009-06-15 | Univ California | Inhibitoren von immunstimulatorischen dna sequenz aktivität |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| EP0994723A1 (en) * | 1997-06-24 | 2000-04-26 | Chiron Corporation | Methods of immunizing adults using anti-meningococcal vaccine compositions |
| PT1630168E (pt) * | 1997-08-27 | 2011-07-20 | Novartis Vaccines & Diagnostic | Compostos miméticos moleculares de péptidos de meningococos do serogrupo b |
| EP1279401B1 (en) | 1997-09-05 | 2008-01-09 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
| US5965714A (en) * | 1997-10-02 | 1999-10-12 | Connaught Laboratories, Inc. | Method for the covalent attachment of polysaccharides to protein molecules |
| DE69841807D1 (de) | 1997-11-06 | 2010-09-16 | Novartis Vaccines & Diagnostic | Neisseriale antigene |
| ATE352624T1 (de) | 1997-11-21 | 2007-02-15 | Serono Genetics Inst Sa | Chlamydia pneumoniae genomische sequenzen und polypeptiden, fragmenten und anwendungen davon für nachweis, prevention und heilung |
| GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
| KR100760221B1 (ko) | 1997-11-28 | 2007-10-30 | 세로노 제네틱스 인스티튜트 에스.에이. | 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도 |
| WO1999032653A1 (en) * | 1997-12-23 | 1999-07-01 | North American Vaccine, Inc. | Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugates vaccines |
| DE69941567D1 (de) | 1998-01-14 | 2009-12-03 | Novartis Vaccines & Diagnostic | Antigene aus neisseria meningitidis |
| US7018637B2 (en) * | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
| US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
| GB9806456D0 (en) * | 1998-03-25 | 1998-05-27 | Smithkline Beecham Biolog | Vaccine composition |
| KR20010042573A (ko) | 1998-04-09 | 2001-05-25 | 장 스테판느 | 애쥬번트 조성물 |
| DE69937419T2 (de) | 1998-05-01 | 2008-07-24 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Neisseria Meningitidis Antigene und Zusammenstellungen |
| AU761495B2 (en) | 1998-05-29 | 2003-06-05 | Chiron Corporation | Combination meningitidis B/C vaccines |
| GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| CN1263510C (zh) | 1998-08-19 | 2006-07-12 | 巴克斯特健康护理股份有限公司 | 多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用 |
| US6128656A (en) * | 1998-09-10 | 2000-10-03 | Cisco Technology, Inc. | System for updating selected part of configuration information stored in a memory of a network element depending on status of received state variable |
| MXPA01003557A (es) | 1998-10-09 | 2004-04-05 | Chiron Corp | Secuencias genomicas de neisseria y metodos para su uso. |
| CN101926993B (zh) | 1998-10-16 | 2013-12-04 | 史密丝克莱恩比彻姆生物有限公司 | 佐剂系统及疫苗 |
| WO2000027994A2 (en) | 1998-11-12 | 2000-05-18 | The Regents Of The University Of California | Chlamydia pneumoniae genome sequence |
| GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
| US6146902A (en) | 1998-12-29 | 2000-11-14 | Aventis Pasteur, Inc. | Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions |
| WO2000056359A2 (en) * | 1999-03-19 | 2000-09-28 | Smithkline Beecham Biologicals S.A. | Vaccine against streptococcus pneumoniae |
| FR2791895B1 (fr) | 1999-03-23 | 2001-06-15 | Pasteur Merieux Serums Vacc | Utilisation de trehalose pour stabiliser un vaccin liquide |
| CA2365914A1 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| PL203951B1 (pl) | 1999-04-19 | 2009-11-30 | Smithkline Beecham Biolog | Kompozycja adiuwantowa, kompozycja szczepionki oraz sposób jej wytwarzania, szczepionka oraz zastosowanie |
| EP2270174A1 (en) | 1999-05-19 | 2011-01-05 | Novartis Vaccines and Diagnostics S.r.l. | Combination neisserial compositions |
| GB9918319D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
| US6531131B1 (en) * | 1999-08-10 | 2003-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for Neisseria meningitidis |
| WO2001021207A2 (en) | 1999-09-24 | 2001-03-29 | Smithkline Beecham Biologicals S.A. | Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
| TR200200777T2 (tr) | 1999-09-24 | 2002-09-23 | Smithkline Beecham Biologicals S.A. | Polioksietilen alkil eteri veya esteriyle en az bir iyonik olmayan yüzey aktif maddeli adjuvant. |
| GB9925559D0 (en) | 1999-10-28 | 1999-12-29 | Smithkline Beecham Biolog | Novel method |
| DK1233784T3 (da) * | 1999-12-02 | 2008-09-01 | Novartis Vaccines & Diagnostic | Præparater og fremgangsmåder til stabilisering af biologiske molekyler efter lyofilisering |
| EP2275129A3 (en) | 2000-01-17 | 2013-11-06 | Novartis Vaccines and Diagnostics S.r.l. | Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins |
| PT1790660E (pt) | 2000-02-28 | 2012-09-17 | Novartis Vaccines & Diagnostic | Expressão heteróloga de proteínas de neisseria |
| US6800455B2 (en) * | 2000-03-31 | 2004-10-05 | Scios Inc. | Secreted factors |
| GB0108364D0 (en) * | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
| SI1296715T2 (sl) | 2000-06-29 | 2016-03-31 | Smithkline Beecham Biologicals S.A. | Multivalentni sestavek cepiva |
| WO2002002606A2 (en) | 2000-07-03 | 2002-01-10 | Chiron S.P.A. | Immunisation against chlamydia pneumoniae |
| GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
| EP1322292B1 (en) * | 2000-09-28 | 2007-01-03 | Novartis Vaccines and Diagnostics, Inc. | Microparticle compositions and methods for the manufacture thereof |
| AU1412702A (en) | 2000-10-27 | 2002-05-06 | Chiron Spa | Nucleic acids and proteins from streptococcus groups a and b |
| EP2957300B1 (en) * | 2001-01-23 | 2021-07-14 | Sanofi Pasteur Inc. | Multivalent meningococcal polysaccharide-protein conjugate vaccine |
| EP1372528B1 (en) * | 2001-04-05 | 2013-01-02 | Novartis Vaccines and Diagnostics, Inc. | Mucosal boosting following parenteral priming |
| GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
| AU2002334844B2 (en) | 2001-10-03 | 2007-08-02 | Novartis Vaccines And Diagnostics, Inc. | Adjuvanted meningococcus compositions |
| BR0308768A (pt) | 2002-03-26 | 2005-02-15 | Chiron Srl | Sacarìdeos modificados possuindo estabilidade melhorada em água |
| GB0302218D0 (en) | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
| RU2378008C2 (ru) | 2002-05-14 | 2010-01-10 | Новартис Вэксинес Энд Дайэгностикс С.Р.Л. | Комбинированные вакцины против бактериального менингита для введения через слизистую оболочку |
| GB0220198D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Modified saccharides,conjugates thereof and their manufacture |
| SI2353608T1 (sl) | 2002-10-11 | 2020-12-31 | Glaxosmithkline Biologicals Sa | Polipeptidna cepiva za široko zaščito proti hipervirulentnim meningokoknim linijam |
| PT2172213E (pt) * | 2003-01-30 | 2013-06-03 | Novartis Ag | Vacinas injetáveis contra múltiplos serogrupos meningocócicos |
| GB0409745D0 (en) * | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
| DK2004225T3 (da) * | 2006-03-22 | 2012-08-06 | Novartis Ag | Programmer for vaccination med meningocockonjugater |
| US10828361B2 (en) * | 2006-03-22 | 2020-11-10 | Glaxosmithkline Biologicals Sa | Regimens for immunisation with meningococcal conjugates |
| GB0822633D0 (en) * | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
| GB2495341B (en) * | 2011-11-11 | 2013-09-18 | Novartis Ag | Fermentation methods and their products |
-
2001
- 2001-06-20 GB GBGB0115176.0A patent/GB0115176D0/en not_active Ceased
-
2002
- 2002-06-20 EP EP10180707A patent/EP2277539A3/en not_active Ceased
- 2002-06-20 CN CNB028124448A patent/CN100482273C/zh not_active Expired - Lifetime
- 2002-06-20 EP EP09075010.0A patent/EP2229954B1/en not_active Expired - Lifetime
- 2002-06-20 MX MXPA03011462A patent/MXPA03011462A/es active IP Right Grant
- 2002-06-20 JP JP2003513590A patent/JP5075317B2/ja not_active Expired - Lifetime
- 2002-06-20 DK DK10179797.5T patent/DK2277536T3/en active
- 2002-06-20 ES ES10007477T patent/ES2387592T5/es not_active Expired - Lifetime
- 2002-06-20 DK DK06075175.7T patent/DK1741442T3/da active
- 2002-06-20 ES ES02755452T patent/ES2261705T5/es not_active Expired - Lifetime
- 2002-06-20 DE DE60237123T patent/DE60237123D1/de not_active Expired - Lifetime
- 2002-06-20 AU AU2002321716A patent/AU2002321716B2/en not_active Expired
- 2002-06-20 TR TR2018/08055T patent/TR201808055T4/tr unknown
- 2002-06-20 CA CA2450203A patent/CA2450203C/en not_active Expired - Lifetime
- 2002-06-20 DE DE60210456T patent/DE60210456T3/de not_active Expired - Lifetime
- 2002-06-20 EP EP09075009.2A patent/EP2216044B1/en not_active Expired - Lifetime
- 2002-06-20 PT PT02755452T patent/PT1401489E/pt unknown
- 2002-06-20 AT AT02755452T patent/ATE322287T1/de active
- 2002-06-20 EP EP10179797.5A patent/EP2277536B1/en not_active Expired - Lifetime
- 2002-06-20 CN CN200910128141.0A patent/CN101524535B/zh not_active Expired - Lifetime
- 2002-06-20 PT PT90750050T patent/PT2184071T/pt unknown
- 2002-06-20 TR TR2018/08026T patent/TR201808026T4/tr unknown
- 2002-06-20 EP EP10007477.2A patent/EP2263688B2/en not_active Expired - Lifetime
- 2002-06-20 ES ES09075010.0T patent/ES2670219T3/es not_active Expired - Lifetime
- 2002-06-20 RU RU2004101284/13A patent/RU2381814C2/ru not_active Application Discontinuation
- 2002-06-20 AT AT10007477T patent/ATE556718T1/de active
- 2002-06-20 NZ NZ544332A patent/NZ544332A/en not_active IP Right Cessation
- 2002-06-20 ES ES09075006.8T patent/ES2573259T3/es not_active Expired - Lifetime
- 2002-06-20 EP EP09075005.0A patent/EP2184071B1/en not_active Expired - Lifetime
- 2002-06-20 PT PT10007477T patent/PT2263688E/pt unknown
- 2002-06-20 US US10/481,457 patent/US8753651B2/en not_active Expired - Lifetime
- 2002-06-20 PT PT101797975T patent/PT2277536T/pt unknown
- 2002-06-20 DE DE122010000040C patent/DE122010000040I1/de active Pending
- 2002-06-20 WO PCT/IB2002/003191 patent/WO2003007985A2/en not_active Ceased
- 2002-06-20 EP EP02755452.6A patent/EP1401489B2/en not_active Expired - Lifetime
- 2002-06-20 CN CN200910128140.6A patent/CN101524534B/zh not_active Expired - Lifetime
- 2002-06-20 ES ES10179797.5T patent/ES2662015T3/es not_active Expired - Lifetime
- 2002-06-20 DK DK09075005.0T patent/DK2184071T3/en active
- 2002-06-20 CA CA2641585A patent/CA2641585C/en not_active Expired - Lifetime
- 2002-06-20 BR BR122019009186A patent/BR122019009186B8/pt not_active IP Right Cessation
- 2002-06-20 NZ NZ529881A patent/NZ529881A/xx not_active IP Right Cessation
- 2002-06-20 DE DE122011000003C patent/DE122011000003I1/de active Pending
- 2002-06-20 ES ES09075005.0T patent/ES2603275T3/es not_active Expired - Lifetime
- 2002-06-20 ES ES09075009.2T patent/ES2670196T3/es not_active Expired - Lifetime
- 2002-06-20 DE DE122010000041C patent/DE122010000041I1/de active Pending
- 2002-06-20 CN CNA2009101281393A patent/CN101524533A/zh active Pending
- 2002-06-20 EP EP10179806.4A patent/EP2277537B1/en not_active Expired - Lifetime
- 2002-06-20 ES ES10179806.4T patent/ES2539134T3/es not_active Expired - Lifetime
- 2002-06-20 DE DE122010000042C patent/DE122010000042I1/de active Pending
- 2002-06-20 AT AT06075175T patent/ATE474594T1/de active
- 2002-06-20 CA CA2730856A patent/CA2730856C/en not_active Expired - Lifetime
- 2002-06-20 DK DK02755452.6T patent/DK1401489T4/da active
- 2002-06-20 DK DK09075006.8T patent/DK2189165T3/en active
- 2002-06-20 PT PT101798064T patent/PT2277537E/pt unknown
- 2002-06-20 EP EP06075175A patent/EP1741442B1/en not_active Expired - Lifetime
- 2002-06-20 PT PT06075175T patent/PT1741442E/pt unknown
- 2002-06-20 DK DK10007477.2T patent/DK2263688T4/da active
- 2002-06-20 EP EP09075006.8A patent/EP2189165B1/en not_active Expired - Lifetime
- 2002-06-20 BR BRPI0210590-0 patent/BRPI0210590B8/pt not_active IP Right Cessation
- 2002-06-20 ES ES06075175T patent/ES2347458T3/es not_active Expired - Lifetime
-
2007
- 2007-07-24 AU AU2007203442A patent/AU2007203442B2/en not_active Expired
-
2009
- 2009-01-09 US US12/351,281 patent/US8889152B2/en not_active Expired - Lifetime
- 2009-01-14 US US12/353,409 patent/US8852606B2/en not_active Expired - Lifetime
- 2009-01-20 US US12/321,420 patent/US20090130147A1/en not_active Abandoned
- 2009-01-20 US US12/321,434 patent/US9782467B2/en not_active Expired - Fee Related
- 2009-01-20 US US12/321,418 patent/US9782466B2/en not_active Expired - Fee Related
- 2009-01-20 US US12/321,417 patent/US9452207B2/en not_active Expired - Fee Related
- 2009-01-20 US US12/321,464 patent/US9358278B2/en not_active Expired - Fee Related
- 2009-02-26 JP JP2009044925A patent/JP5380111B2/ja not_active Expired - Lifetime
- 2009-02-26 JP JP2009044924A patent/JP5220658B2/ja not_active Expired - Lifetime
- 2009-03-11 RU RU2009108660/10A patent/RU2528066C2/ru active
-
2010
- 2010-09-13 BE BE2010C033C patent/BE2010C033I2/fr unknown
- 2010-09-13 NL NL300458C patent/NL300458I2/nl unknown
- 2010-09-13 FR FR10C0043C patent/FR10C0043I1/fr active Active
- 2010-09-13 BE BE2010C031C patent/BE2010C031I2/fr unknown
- 2010-09-13 NL NL300459C patent/NL300459I2/nl unknown
- 2010-09-13 FR FR10C0044C patent/FR10C0044I1/fr active Active
- 2010-09-13 NL NL300460C patent/NL300460I2/nl unknown
- 2010-09-13 BE BE2010C032C patent/BE2010C032I2/fr unknown
- 2010-09-13 FR FR10C0042C patent/FR10C0042I1/fr active Active
- 2010-09-14 LU LU91734C patent/LU91734I2/fr unknown
- 2010-09-14 LU LU91733C patent/LU91733I2/fr unknown
- 2010-09-14 LU LU91732C patent/LU91732I2/fr unknown
- 2010-10-11 CY CY20101100902T patent/CY1110820T1/el unknown
- 2010-11-19 AU AU2010246331A patent/AU2010246331B2/en not_active Expired
-
2011
- 2011-01-13 BE BE2011C001C patent/BE2011C001I2/fr unknown
- 2011-01-13 LU LU91778C patent/LU91778I2/fr unknown
- 2011-01-14 FR FR11C0001C patent/FR11C0001I2/fr active Active
- 2011-01-18 CY CY2011001C patent/CY2011001I2/el unknown
-
2012
- 2012-08-03 CY CY20121100693T patent/CY1113020T1/el unknown
- 2012-10-05 JP JP2012222942A patent/JP2013007057A/ja not_active Withdrawn
-
2016
- 2016-05-18 CY CY20161100432T patent/CY1117528T1/el unknown
- 2016-10-21 CY CY20161101065T patent/CY1118130T1/el unknown
- 2016-10-31 US US15/339,741 patent/US10716841B2/en not_active Expired - Fee Related
-
2018
- 2018-03-30 CY CY20181100356T patent/CY1120499T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60210456T3 (de) | Solubisierung von kapseln polysacchariden | |
| DE69627652T2 (de) | Verbesserte meningokokken polysaccharid-konjugat vakzine | |
| AU2002321716A1 (en) | Capsular polysaccharide solubilisation and combination vaccines | |
| AU2014218428B2 (en) | Capsular polysaccharide solubilisation and combination vaccines | |
| AU2012230097A1 (en) | Capsular polysaccharide solubilisation and combination vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8363 | Opposition against the patent | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: NOVARTIS VACCINES AND DIAGNOSTICS S.R.L., SIEN, IT |
|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: NOVARTIS AG, BASEL, CH |
|
| V448 | Application of spc |
Free format text: PRODUCT NAME: MENINGOKOKKEN-GRUPPE A-OLIGOSACCHARID KONJUGIERT AN CORYNEBACTERIUM DIPHTHERIAECRM197-PROTEIN IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/614/001, 20100315 Spc suppl protection certif: 12 2010 000 040 Filing date: 20100914 Free format text: PRODUCT NAME: MENINGOKOKKEN-GRUPPE Y-OLIGOSACCHARID KONJUGIERT AN CORYNEBACTERIUM DIPHTHERIAECRM197-PROTEIN IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/614/001, 20100315 Spc suppl protection certif: 12 2010 000 041 Filing date: 20100914 Free format text: PRODUCT NAME: MENINGOKOKKEN-GRUPPE W135-OLIGOSACCHARID KONJUGIERT AN CORYNEBACTERIUM DIPHTHERIAE CRM197-PROTEIN IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/614/001, 20100315 Spc suppl protection certif: 12 2010 000 042 Filing date: 20100914 |